Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28954129 | 0.85 | LMNA (0.33) | TSHRLMNAUSP2ALDH1A1CYP1A2 | |
| SCHEMBL19937052 | 0.80 | TSHR (0.30) | TSHR | |
| SCHEMBL24993020 | 0.72 | TSHR (0.33) | TSHR | |
| SCHEMBL25880206 | 0.71 | LMNA (0.31) | LMNAUSP2ALDH1A1CYP1A2BLM | |
| SCHEMBL21160683 | 0.70 | TSHR (0.32) | TSHR | |
| SCHEMBL24780994 | 0.68 | TSHR (0.35) | TSHRMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL18403589 | 0.68 | TSHR (0.30) | TSHR | |
| SCHEMBL27289579 | 0.68 | — | — | |
| SCHEMBL14494687 | 0.67 | LMNA (0.45) | TSHRLMNAUSP2ALDH1A1CYP1A2 | |
| SCHEMBL17683993 | 0.67 | TSHR (0.39) | TSHRMEN1KMT2ALMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2160606-A2 | TACE INHIBITORS IN THE TREATMENT OF ACNE | Galderma Research & Development (FR) | 2010-03-10 | — | — | EP | claimed |
| WO-2009004247-A2 | TACE INHIBITORS IN THE TREATMENT OF ACNE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-01-08 | — | — | WO | claimed |
| US-20100168089-A1 | UTILIZATION OF TACE INHIBITORS FOR THE TREATMENT OF ACNE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168089-A1 | UTILIZATION OF TACE INHIBITORS FOR THE TREATMENT OF ACNE | MMP17, MMP25, TIMP3 | TSHR 1655/4885MEN1 4016/4885KMT2A 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.